Misplaced Pages

BMS-345541: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 14:39, 4 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEMBL').← Previous edit Latest revision as of 19:52, 20 December 2023 edit undoJJMC89 bot III (talk | contribs)Bots, Administrators3,683,453 editsm Moving Category:Merck brands to Category:Drugs developed by Merck per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands 
(20 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458977224
| IUPAC_name = 4-(2′-Aminoethyl)amino-1,8-dimethylimidazoquinoxaline | IUPAC_name = 4-(2′-Aminoethyl)amino-1,8-dimethylimidazoquinoxaline
| image = BMS-345541.png | image = BMS-345541 structure.svg
| alt = | alt =
| caption = | caption =

<!--Clinical data--> <!--Clinical data-->
| tradename = | tradename =
Line 16: Line 19:
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration =

<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
Line 23: Line 25:
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =
<!--Identifiers-->
| IUPHAR_ligand = 5669
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 445430-58-0
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 26SU0NEF5F


<!--Identifiers-->
| CAS_number =
| ATCvet = | ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised --> | ATC_prefix =
| ATC_suffix = | ATC_suffix =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| PubChem =
| DrugBank = | DrugBank =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 249697 -->
| ChEMBL = 249697
| chemical_formula = C14 H17 N5
| PubChem = 9813758

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| molecular_weight = 255.3
| ChemSpiderID = 7989508
| smiles = n1c3c(n2c(cnc2c1NCCN)C)cc(cc3)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C14H17N5/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = PSPFQEBFYXJZEV-UHFFFAOYSA-N
<!--Chemical data-->
| C=14 | H=17 | N=5
}} }}


'''BMS-345541''', marketed by ], is an ], cell-permeable ] compound. It is an ] site-binding inhibitor with a primary target of IKK-2 and blocks the NF-kB-dependent ] in mice.<ref>The Journal of Biological Chemistry. 2003. 278. 1450-1456.</ref> '''BMS-345541''', developed by ], is an ], cell-permeable ] compound. It is an ] site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent ] in mice.<ref>The Journal of Biological Chemistry. 2003. 278. 1450-1456.</ref>

It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.<ref name=NCT></ref>


==References== ==References==
Line 43: Line 59:


] ]
]